A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma

NCT03244306 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt

Sponsor

Seattle Children's Hospital